Personalis (PSNL) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Personalis will report Q1 2026 results after the market closes on May 7, with analysts forecasting earnings of ($0.23) per share and revenue of $14.452 million and a call scheduled for 5:00 PM ET.
• The company beat the prior quarter's estimates (reported ($0.26) vs. consensus ($0.31)) with $17.35 million in revenue, but remains unprofitable with a negative ROE (39.13%) and net margin (-116.69%); analysts expect about ($1.00) EPS for the current and next fiscal year.
• Shares opened at $5.04 (down 8.4%), market cap ~$527.6M and a 52‑week range of $3.62–$11.50, while the consensus rating is a "Moderate Buy" with a $11.50 target (five Buys, one Hold, one Sell).

Personalis (NASDAQ:PSNL - Get Free Report) will likely be issuing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $14.4520 million for the quarter. Interested persons may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 5:00 PM ET.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.05. The firm had revenue of $17.35 million for the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%. On average, analysts expect Personalis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Personalis Stock Down 8.4%

Shares of Personalis stock opened at $5.04 on Thursday. The business has a 50 day moving average of $7.14 and a 200 day moving average of $8.32. Personalis has a 52 week low of $3.62 and a 52 week high of $11.50. The company has a market cap of $527.58 million, a PE ratio of -5.54 and a beta of 2.20.

Institutional Trading of Personalis

Hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its stake in shares of Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock worth $275,000 after acquiring an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd grew its holdings in Personalis by 75.6% in the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company's stock worth $269,000 after purchasing an additional 33,044 shares during the period. Goldman Sachs Group Inc. grew its holdings in Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company's stock worth $998,000 after purchasing an additional 101,706 shares during the period. Focus Partners Wealth bought a new position in shares of Personalis during the first quarter valued at approximately $47,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Personalis by 505.6% during the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company's stock valued at $193,000 after purchasing an additional 24,621 shares during the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on PSNL shares. Needham & Company LLC boosted their price objective on shares of Personalis from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Friday, February 27th. BTIG Research boosted their price target on shares of Personalis from $12.00 to $13.00 and gave the company a "buy" rating in a research report on Wednesday, February 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of Personalis in a research note on Tuesday, April 21st. Wall Street Zen upgraded shares of Personalis from a "sell" rating to a "hold" rating in a report on Sunday, March 8th. Finally, Guggenheim lifted their price objective on Personalis from $12.00 to $13.00 and gave the company a "buy" rating in a research report on Monday, January 26th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.50.

About Personalis

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.